Every day researchers work towards finding new breakthroughs in cancer. Clinical trials play a pivotal role in bringing that defeat closer.
Clinical trials test promising new treatments on people to see if they are better than existing cancer treatments. The trial process is long starting many years before an actual treatment can be used.
By joining a clinical trial you are helping to create new breakthroughs in cancer research. Hundreds of thousands of people all over the world have taken part in clinical trials that have lead to safer and more effective treatments for many cancers.
It is important to note that not all cancer patients are eligible to take part in clinical trials and there are not clinical trials for all types of cancer.
You may decide to join a clinical trial because:
- The treatment you receive will be at least the best available for your illness.
- Your health may improve because of the treatment you receive.
- You may receive a treatment you would not otherwise have access to.
- Your health will be carefully checked by the treatment team running the trial.
- You will be part of the worldwide effort to improve cancer treatment.
For more information on clinical trials please click here.
If you would like information regarding any of the below clinical trials, please contact the appropriate Clinical trials manager:
Ashford Cancer Centre: Helen Daykin, +61 8 8292 2240
Flinders Medical Centre: Alex Scott-Hoy, +61 8 8204 4830
The Queen Elizabeth: Sue Yeend, +61 8 8222 6148
Lyell McEwin Hospitals: Julie Rowe or Rohit Joshi +61 8 8282 0833
Royal Adelaide Hospital: Anne Milton, +61 8 7074 2342
Current clinical trials for lung & mesothelioma cancer
|Recruiting||ADAURA A Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, following Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA)||Flinders Medical Centre|
|Not Yet Recruiting||Bayer Basket Study - Phase 1b basket study of anetumab ravansine in patients with mesothelin expressing advanced or recurrent solid tumours (TNBC/Thymic/Cholaniocarcinoma/pancrea tic adenocarcinoma)||Flinders Medical Centre|
|Recruiting||BMS 227 An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus platinum doublet chemotherapy versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer||Lyell McEwin Hospital|
|Recruiting||BMS 384 A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks||The Lyell McEwin Hospital|
|Recruiting||BR.31 A PHASE III PROSPECTIVE DOUBLE BLIND PLACEBO CONTROLLED RANDOMIZED STUDY OF ADJUVANT MEDI4736 IN COMPLETELY RESECTED NON-SMALL CELL LUNG CANCER||Flinders Medical Centre|
|Recruiting||BR31 - A Phase III Prospective Double Blind Randomized Study Of Adjuvant Medi4736 in completely resected Non-Small Cell Lung Cancer||Royal Adelaide Hospital|
|Recruiting||CA209-384 CHECKMATE A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240mg Every 2 Weeks vs Nivolumab 480mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received up to 12 Months of Nivolumab at 3mg/kg or 240mg Every 2 Weeks.||Ashford Cancer Centre Research|
|Recruiting||CEFG816X2201C - A phase II, multicentre, parallel group open label study of EGF816 in combination with Nivolumab in adult patients with EGFR mutated non-small cell lung cancer and INC280 in combination with Nivolumab in cMET positive adult patients with NSCLC||Royal Adelaide Hospital|
|Recruiting||CheckMate 384 (Lung) A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks||Flinders Medical Centre|
|Recruiting||Javelin lung 100. A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of recurrent or Stage IV PD-L1+ non small cell lung cancer.||The Queen Elizabeth Hospital|
|Recruiting||KEYNOTE-604 A Phase III Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab (MK- 3475/SCH900475) in Combination with Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line Treatment of Subjects with Extensive Stage Small Cell Lung Cancer||The Lyell McEwin Hospital|
|Mesothelioma QOL - An Observational Study of Health-related 413.14 Quality of Life in People with Malignant Mesothelioma||Flinders Medical Centre|
|Recruiting||Mirati Lung Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor||Flinders Medical Centre|
|Not yet recruiting||NIVORAD A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer progressing after first or second line chemotherapy||Royal Adelaide Hospital|
|Recruiting||A Phase 2 Study of MM-121 in Combination with Docetaxel or Pemetrexed versus Docetaxel or Pemetrexed Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer||Flinders Medical Centre|
|Recruiting||TROG 11.03 - A Randomised Phase III Trials of High Dose Palliative Radiotherapy (HDPRT) versus Concurrent Chemotherapy + HDPRT (C-HDPRT) In patients with good performance status, locally Advanced / Small Volume Metastatic NSCLC not suitable for Radical Chemo-radiother||Flinders Medical Centre|
|Recruiting||TROG 13.01 - A randomised phase 2 trial of stereotactic ablative fractionated radiotherapy versus radiosurgery for oligometastatic neoplasia to the lung||Royal Adelaide Hospital|